science
Schall Law Firm Announces Investigation into ORIC Pharmaceuticals on Behalf of Investors
The Schall Law Firm announced an investigation on April 22, 2026, into claims that ORIC Pharmaceuticals, Inc. violated securities laws through false or misleading statements. The probe targets disclosures related to investors. ORIC, which trades on NASDAQ under ORIC, recently announced rinzimetostat (ORIC-944).
Apr 22, 9:56 AM·1m read1 source
Substrate placeholder — needs reviewAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
LOS ANGELES, April 22, 2026 (Substrate) -- The Schall Law Firm announced an investigation into claims on behalf of investors of ORIC Pharmaceuticals, Inc. for violations of securities laws. The announcement came on Tuesday from the national shareholder rights litigation firm based in Los Angeles.
The investigation focuses on whether ORIC Pharmaceuticals, Inc. issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Benzinga reported that the probe examines potential lapses in transparency affecting shareholder interests.
ORIC Pharmaceuticals, Inc. trades on NASDAQ under the ticker symbol ORIC. ORIC Pharmaceuticals, Inc. announced rinzimetostat (ORIC-944), a development that has drawn scrutiny in the context of the investigation.
The firm stated it is pursuing claims to protect investors who may have suffered losses due to alleged securities violations. No specific timeline for the investigation's outcome has been disclosed.
